SAT0292 Evaluation of radiographic progression after 4 years of etanercept (ETN) in ankylosing spondylitis (AS): results from the open-label extension (OLE) of the phase 3 clinical trial

Abstract

BackgroundETN was well tolerated and showed clinical efficacy (ASAS 20: ETN 59%, placebo 28%, p<0.0001) through 24 wks in a phase 3 AS trial;1 efficacy was sustained up to 2...